Scandion Oncology (Nasdaq: SCOL), a Danish biotech developing medicines for treatment-resistant cancer, has announced that president and chief executive Bo Rode Hansen (pictured above, center) will leave his position with immediate effect by mutual agreement.
Johnny Stilou (pictured right), who has been Scandion's chief financial officer since July 2021, has been appointed acting CEO effective immediately, with the process to identify a new permanent boss having already started.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze